UNSPSC 51283715: Cefamandole sodium

This classification denotes a cephalosporin antibiotic with the molecular formula C18H17N6O5S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IY6234ODVR, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-mandelamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt, d- but more generally known as cefamandole sodium, which bears US NIH Compound Identifier 34779.

UNSPSC 51283715 Cefamandole sodium, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally identifies a specific third-generation cephalosporin antibiotic, yet the four most recent opportunities tagged to this code procure naloxone and drug deactivation systems, therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs, medical and first aid supplies for fire rescue, and generic multi-source pharmaceuticals with OTC products through cooperative purchasing. None of these solicitations actually involve cefamandole sodium or narrow-spectrum injectable antibiotics; the mismatch suggests either cataloging error in the source data or use of the code as a placeholder within a broader pharmaceutical acquisition framework.

The geographic spread across recent opportunities spans Florida (Seminole County), Texas (Health and Human Services Commission), Florida again (City of Tampa), and Minnesota (MMCAP, which serves multiple states including Oregon). Issuing bodies include a county health department, a state health and human services agency, a municipal fire department, and a multistate cooperative purchasing entity. The most recent identifiable opportunity is Seminole County's IFB for naloxone and drug deactivation systems (1,900 units and 800 units annually, respectively, due July 26, 2023, though the posting date of June 30, 2026 creates a timeline inconsistency in the source). The City of Tampa's IFB for medical and first aid supplies (169 line items, $700,000 estimated value, due March 13, 2026) and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) represent the clearest recent municipal and cooperative-purchasing activity, though neither targets cefamandole sodium directly. No specific set-asides or disadvantaged-enterprise restrictions are reported for pharmaceutical procurement under this code, though the Tampa solicitation designates a sheltered market for certified Small Local Business Enterprises with a 5% bid discount.